Treace Medical Concepts, Inc. (TMCI) Stock Price & Analysis

Treace Medical Concepts, Inc. (TMCI) closed at USD 4.83 on Wednesday, October 28, 2026, up 6.15% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 4.55; the Oct 28, 2026 session ranged USD 4.43–4.83 on volume of 188,463 shares. Market capitalization is $314.12M, with a 52-week range of USD 1.17–6.91 (NMS). Source: Nexqual, retrieved October 29, 2026 at 07:22 UTC.

Also available as compact Markdown for AI agents: nexqual.com/TMCI.md

Key facts (TMCI)

• Last four reported quarters (through Jun 30, 2026): revenue $205M, net income -$59.5M (-29.0% margin), free cash flow -$25.0M (SEC filings).
• Insider open-market purchases, last ~7 months: 5 Form 4 filings, $1.4M; 5 by opportunistic insiders, 0 by routine insiders.
• Analysts: Hold (mean 3.20 on a 1–5 scale) (5 analysts), mean target USD 5.5 (range 4.5–7).
• Total return with dividends: 1Y -26.3% vs S&P 500 +13.6%; 5Y -79.0% vs S&P 500 +79.8%.
• Next earnings: 2026-11-06, EPS estimate USD -0.25, revenue estimate $47.7M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TMCI)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (TMCI)

P/S 1.5x · EV/Sales 1.6x · P/B 4.6x · FCF yield -7.97% · Earnings yield -18.95% · Net debt $13.6M · EV $328M

Insider purchases (SEC Form 4, open-market, last ~7 months) (TMCI)

5 purchases, $1.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (TMCI)

Consensus Hold (mean 3.20 on a 1–5 scale), 5 analysts; mean target USD 5.5 (low 4.5, high 7).

Rating changes, last 120 days:

Total return (dividends reinvested) (TMCI)

TMCI earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

TMCI recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

TMCI suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 27, 2026.

TMCI company outlook (results filed Aug 7, 2026)

• “The Company is raising its full-year 2026 revenue guidance to be in the range of $204 million to $212 million, representing a decline of 4% to 0% compared to full-year 2025.”
• “This compares to previous revenue guidance of $202 million to $212 million.”
• “The Company is updating its expectation of a loss in Adjusted EBITDA in the range of $3.0 million to $5.0 million for full year 2026, as compared to previous guidance of a loss in the range of $4.0 million to $6.0 million.”
• “The Company reported a loss of $3.9 million in the full-year 2025.* The Company reiterates its expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025.”

Quoted word-for-word from the SEC 8-K results press release.

TMCI analyst estimates and revisions

TMCI options: expected move

Options price a move of about ±25.7% (±$1.24) by Dec 18, 2026, which includes earnings on Nov 6, 2026. Over the last 8 reports the stock moved ±13.4% on average.

30-day implied volatility 85.3% vs 54.4% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 07:22 UTC)

Technical Analysis (TMCI)

Nexqual's technical model rates TMCI "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 07:22 UTC.

Analyst Ratings (TMCI)

Wall Street analysts rate TMCI "Hold" based on 5 analysts, with a mean price target of USD 5.5 (range USD 4.5–7), per Nexqual as of October 29, 2026 at 07:22 UTC.

Earnings (TMCI)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 07:22 UTC.

Financials & Fundamentals (TMCI)

Source: Nexqual, October 29, 2026 at 07:22 UTC.

Financial Health Score (TMCI)

Nexqual rates Treace Medical Concepts, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 07:22 UTC.

Ownership (TMCI)

Source: Nexqual, October 29, 2026 at 07:22 UTC.

Leadership (TMCI)

Treace Medical Concepts, Inc. is led by John T. Treace, Founder, Chairman & CEO, per Nexqual as of October 29, 2026 at 07:22 UTC.

Major Backers & Investors (TMCI)

Notable institutional backers of Treace Medical Concepts, Inc. include Armistice Capital, LLC, Bank of America Corporation, Gagnon Securities, LLC, according to Nexqual as of October 29, 2026 at 07:22 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 07:22 UTC.

From Treace Medical Concepts, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• We have pioneered our proprietary Lapiplasty 3D Bunion Correction System—a combination of innovative instruments, implants and surgical methods designed to correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion.
• Class I includes devices with the lowest risk to the patient and generally require adherence to the FDA's General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation ("QSR"), facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials.
• Since it can be implanted through a small 2cm incision, the SpeedPlate technology not only offers broad applicability with our proprietary systems but may also be used for other common bone fusion procedures in the foot.
• Our knowledge and experience, creative product development, sales and marketing staff and trade secret information, with respect to manufacturing processes, materials and product design, are as important as our patents in maintaining our proprietary product lines.

Partnerships

• As products are commercialized with the assistance of the surgeon consultants, we may agree to enter into a royalty agreement if the consultant's contributions to the product are novel, significant and innovative.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to substantial government regulation that could have a material adverse effect on our business.
• Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future pre-market clearances or approvals, and could result in a substantial modification to our business practices and operations.
• Our relationships with customers, physicians, other health care providers, and third-party payors are subject to federal and state health care fraud and abuse laws, false claims laws, physician payment transparency laws and other health care laws and regulations. If we or our employees, independent contractors, consultants, service providers, or vendors violate these laws, we could face substantial penalties.
• We may not receive, or may be delayed in receiving, the necessary clearances or approvals for our future products or modifications to our current products, and failure to timely obtain necessary clearances or approvals for our future products or modifications to our current products would adversely affect our ability to grow our business.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:22 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt